PDSB insider filings
PDS Biotechnology Corp — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-10-21. Screen PDSB transaction legs live →
Insider transaction summary — last 90 days
2026-07-29 to 2026-10-27, from the filings listed below: 8 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 3.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Dawson John Andrew — Director | 2 | — | — | 1 |
| Ramsdell Deborah — Director | 2 | — | — | 1 |
| Wendel Bruce — Director | 2 | — | — | 1 |
| Banaag Arnold James — Director | 1 | — | — | — |
| SOON-SHIONG PATRICK — Director, 10% owner & Nant Capital, LLC — 10% owner | 1 | — | — | — |
Recent insider filings — PDS Biotechnology Corp
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-21 | 4 | Dawson John Andrew — Director | Grant/award (A): 22,700 (derivative) @ $0 | EDGAR |
| 2026-10-21 | 3 | Dawson John Andrew — Director | Holdings only — no transactions reported | EDGAR |
| 2026-10-20 | 4 | Wendel Bruce — Director | Grant/award (A): 22,700 (derivative) @ $0 | EDGAR |
| 2026-10-20 | 4 | Ramsdell Deborah — Director | Grant/award (A): 22,700 (derivative) @ $0 | EDGAR |
| 2026-10-20 | 3 | Ramsdell Deborah — Director | Holdings only — no transactions reported | EDGAR |
| 2026-10-20 | 3 | Wendel Bruce — Director | Holdings only — no transactions reported | EDGAR |
| 2026-09-21 | 3 | Banaag Arnold James — Director | Holdings only — no transactions reported | EDGAR |
| 2026-09-21 | 3 | SOON-SHIONG PATRICK — Director, 10% owner Nant Capital, LLC — 10% owner | Holdings only — no transactions reported | EDGAR |
| 2026-03-03 | 4 | BEDU-ADDO FRANK — President/CEO, Director | Grant/award (A): 548,782 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | CONN GREGORY — Chief Scientific Officer | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Shepard Kirk V. — Chief Medical Officer | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Brown Spencer D. — Senior VP, General Counsel | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Toutain Stephan — Chief Operating Officer | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Freitag Gregory Gene — Director | Grant/award (A): 54,876 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Iliev Ilian — Director | Grant/award (A): 54,876 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Ali-Jackson Kamil — Director | Grant/award (A): 54,876 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Boesgaard Lars — Chief Financial Officer | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Glover Stephen C. — Director | Grant/award (A): 54,876 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | BRAWLEY OTIS W — Director | Grant/award (A): 54,876 (derivative) @ $0 | EDGAR |
| 2025-07-25 | 4 | BEDU-ADDO FRANK — President/CEO, Director | Grant/award (A): 300,000 (derivative) @ $0 · Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-07-25 | 4 | Shepard Kirk V. — Chief Medical Officer | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-07-25 | 4 | Brown Spencer D. — Senior VP, General Counsel | Grant/award (A): 56,000 (derivative) @ $0 · Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-07-25 | 4 | CONN GREGORY — Chief Scientific Officer | Grant/award (A): 46,648 (derivative) @ $0 · Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-07-25 | 4 | Toutain Stephan — Chief Operations Officer | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-07-25 | 4 | Boesgaard Lars — Chief Financial Officer | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | Iliev Ilian — Director | Grant/award (A): 22,700 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | Ali-Jackson Kamil — Director | Grant/award (A): 22,700 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | Freitag Gregory Gene — Director | Grant/award (A): 22,700 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | Glover Stephen C. — Director | Grant/award (A): 22,700 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | BRAWLEY OTIS W — Director | Grant/award (A): 22,700 (derivative) @ $0 | EDGAR |
| 2025-03-03 | 4 | Freitag Gregory Gene — Director | Purchase (P): 15,060 @ $1.66 · Purchase (P): 15,060 (derivative) | EDGAR |
| 2025-03-03 | 4 | Glover Stephen C. — Director | Purchase (P): 15,061 @ $1.66 · Purchase (P): 15,061 (derivative) | EDGAR |
| 2024-06-25 | 4 | Freitag Gregory Gene — Director | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2024-06-25 | 4 | Iliev Ilian — Director | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2024-06-25 | 4 | Ali-Jackson Kamil — Director | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2024-06-25 | 4 | SYKES RICHARD — Director | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2024-06-25 | 4 | Glover Stephen C. — Director | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2024-06-25 | 4 | BRAWLEY OTIS W — Director | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2024-05-02 | 4 | Toutain Stephan — Chief Operations Officer | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2024-01-23 | 4 | Shepard Kirk V. — Chief Medical Officer | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2023-12-04 | 4 | Boesgaard Lars — Chief Financial Officer | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2023-07-17 | 4 | Freitag Gregory Gene — Director | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2023-07-17 | 4 | Ali-Jackson Kamil — Director | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2023-07-17 | 4 | Iliev Ilian — Director | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2023-07-17 | 4 | SYKES RICHARD — Director | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2023-07-17 | 4 | Glover Stephen C. — Director | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2023-07-17 | 4 | BRAWLEY OTIS W — Director | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2023-01-06 | 4 | BEDU-ADDO FRANK — President/CEO, Director | Grant/award (A): 385,300 (derivative) @ $0 | EDGAR |
| 2023-01-06 | 4 | WOOD LAUREN — Chief Medical Officer | Grant/award (A): 110,800 (derivative) @ $0 | EDGAR |
| 2023-01-06 | 4 | HILL MATTHEW C — Chief Financial Officer | Grant/award (A): 161,200 (derivative) @ $0 | EDGAR |
Recent 8-K events — PDS Biotechnology Corp
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-10-21 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-20 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-06 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-22 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-21 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-14 | 8-K | 1.02 — Termination of a Material Definitive Agreement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-08 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-04 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-25 | 8-K | ? 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-08-19 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=PDSB returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs